In The Lancet Oncology, Wen-Zhao Zhong and colleagues report findings of the ADJUVANT study.¹ 222 patients with completely resected, stage II–IIIA (N1–N2), EGFR-mutant non-small-cell lung cancer (NSCLC) were randomly assigned to either four cycles of adjuvant vinorelbine plus cisplatin or 24 months of gefitinib—an EGFR tyrosine kinase inhibitor. Disease-free survival (the primary endpoint) was significantly longer for patients assigned gefitinib than for those assigned cisplatin-based chemotherapy (median 28·7 months, 95% CI 24·9–32·5 vs 18·0 months, 13·6–22·3; hazard ratio [HR] 0·60, 95% CI 0·42–0·87; p=0·0054).

中文翻译：

---

肺癌真正的辅助EGFR靶向治疗的问题

在《柳叶刀肿瘤》杂志上，钟文照及其同事报告了ADJUVANT研究的发现。^将1 222例完全切除，II–IIIA期（N1 – N2），EGFR突变的非小细胞肺癌（NSCLC）患者随机分为四个周期的长春瑞滨联合顺铂辅助治疗或24个月吉非替尼（EGFR）治疗酪氨酸激酶抑制剂。接受吉非替尼治疗的患者的无病生存时间（主要终点）显着长于接受顺铂化疗的患者（中位28·7个月，95％CI 24·9–32·5 vs 18·0个月，13·6 –22·3；危险比[HR] 0·60，95％CI 0·42-0·87； p = 0·0054）。